BRIGHT MINDS BIOSCIENCES INC (DRUG) Stock Fundamental Analysis

NASDAQ:DRUG • CA10919W4056

80.4 USD
-2.41 (-2.91%)
Last: Mar 3, 2026, 12:27 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall DRUG gets a fundamental rating of 2 out of 10. We evaluated DRUG against 520 industry peers in the Biotechnology industry. DRUG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DRUG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year DRUG has reported negative net income.
  • DRUG had a negative operating cash flow in the past year.
  • In the past 5 years DRUG always reported negative net income.
  • DRUG had a negative operating cash flow in each of the past 5 years.
DRUG Yearly Net Income VS EBIT VS OCF VS FCFDRUG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -5M -10M

1.2 Ratios

  • With a decent Return On Assets value of -14.49%, DRUG is doing good in the industry, outperforming 80.00% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -14.91%, DRUG belongs to the top of the industry, outperforming 85.77% of the companies in the same industry.
Industry RankSector Rank
ROA -14.49%
ROE -14.91%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DRUG Yearly ROA, ROE, ROICDRUG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • DRUG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRUG Yearly Profit, Operating, Gross MarginsDRUG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, DRUG has more shares outstanding
  • Compared to 5 years ago, DRUG has more shares outstanding
  • The debt/assets ratio for DRUG has been reduced compared to a year ago.
DRUG Yearly Shares OutstandingDRUG Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2024 2025 2M 4M 6M
DRUG Yearly Total Debt VS Total AssetsDRUG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • DRUG has an Altman-Z score of 278.01. This indicates that DRUG is financially healthy and has little risk of bankruptcy at the moment.
  • DRUG has a Altman-Z score of 278.01. This is amongst the best in the industry. DRUG outperforms 99.62% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that DRUG is not too dependend on debt financing.
  • DRUG's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. DRUG outperforms 52.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 278.01
ROIC/WACCN/A
WACCN/A
DRUG Yearly LT Debt VS Equity VS FCFDRUG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 36.10 indicates that DRUG has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 36.10, DRUG belongs to the top of the industry, outperforming 98.85% of the companies in the same industry.
  • DRUG has a Quick Ratio of 36.10. This indicates that DRUG is financially healthy and has no problem in meeting its short term obligations.
  • DRUG has a better Quick ratio (36.10) than 98.85% of its industry peers.
Industry RankSector Rank
Current Ratio 36.1
Quick Ratio 36.1
DRUG Yearly Current Assets VS Current LiabilitesDRUG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • DRUG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -152.75%.
EPS 1Y (TTM)-152.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-249.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DRUG. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRUG Price Earnings VS Forward Price EarningsDRUG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRUG Per share dataDRUG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DRUG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BRIGHT MINDS BIOSCIENCES INC

NASDAQ:DRUG (3/3/2026, 12:27:54 PM)

80.4

-2.41 (-2.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-13
Inst Owners73.1%
Inst Owner Change31.27%
Ins Owners14.52%
Ins Owner ChangeN/A
Market Cap782.29M
Revenue(TTM)N/A
Net Income(TTM)-12.23M
Analysts85.71
Price TargetN/A
Short Float %6.02%
Short Ratio2.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.03
P/tB 13.03
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS6.17
TBVpS6.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.49%
ROE -14.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 36.1
Quick Ratio 36.1
Altman-Z 278.01
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-152.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-249.41%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-395.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-369.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-369.76%
OCF growth 3YN/A
OCF growth 5YN/A

BRIGHT MINDS BIOSCIENCES INC / DRUG FAQ

What is the ChartMill fundamental rating of BRIGHT MINDS BIOSCIENCES INC (DRUG) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DRUG.


What is the valuation status of BRIGHT MINDS BIOSCIENCES INC (DRUG) stock?

ChartMill assigns a valuation rating of 0 / 10 to BRIGHT MINDS BIOSCIENCES INC (DRUG). This can be considered as Overvalued.


How profitable is BRIGHT MINDS BIOSCIENCES INC (DRUG) stock?

BRIGHT MINDS BIOSCIENCES INC (DRUG) has a profitability rating of 1 / 10.


How financially healthy is BRIGHT MINDS BIOSCIENCES INC?

The financial health rating of BRIGHT MINDS BIOSCIENCES INC (DRUG) is 6 / 10.